Eloralintide: What It Is, Trial Results and Dosage

Dosing: the phase 2 trial doses.

What is eloralintide?

Eloralintide is an investigational Eli Lilly peptide, given as a once-weekly injection under the skin. It selectively activates the amylin receptor.

That target sets it apart from the other weight-loss peptides:

• Semaglutide and tirzepatide act on the GLP-1 receptor, and tirzepatide also on the GIP receptor.
• Mazdutide and survodutide have glucagon-receptor activity.
• Cagrilintide, an earlier amylin-pathway peptide, shares its target, but it is a separate molecule from a different company.

Eloralintide structure

Molecular formula

C₂₀₁H₃₁₉N₄₉O₆₅S₂

Molecular weight

4526.2 g/mol

Length

37 amino acids

Sequence

XCNTATCATGXLAEFLVRSSNNFGPKLPPTEVGSNTY

Modifications

Non-standard residues per FDA: Cys2 and Cys7 joined by a methylene thioacetal bridge instead of a disulfide; ornithine at 11; alpha-methyl-Phe at 15; N-methyl-Asn at 22; Lys26 carries a C20 fatty diacid via two gamma-Glu; C-terminal tyrosinamide. Position 1 (X) is a non-standard N-terminal residue in KEGG's listing.

PubChem's eloralintide record (CID 175663130) has the right formula but no stereochemistry, so no diagram is shown.

Sequence checked against FDA Global Substance Registration System (UNII 73G3354J8W).

Eloralintide trial results: what the research shows

Its only published human efficacy trial was a 48-week, multicentre, double-blind, randomised, placebo-controlled phase 2 study in 263 adults with obesity or overweight Billings 2025 - Billings LK, Hsia S, Bays H et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025;406(10520):2631-2643., in the references below. Weight fell by 9.5% to 20.1% across the dose arms, against 0.4% on placebo. The most common adverse events were mild-to-moderate gut symptoms.

That is one real trial, not a long-term or replicated result. Lilly has said it plans Phase 3 enrollment based on these findings.

Eloralintide dosage

No dose is FDA-approved, because there is no approved product. The phase 2 trial tested 1, 3, 6 and 9 mg weekly, both fixed and stepped up. The eloralintide dosage page has the full sourcing and explains why no separate common-practice protocol could be established.

Eloralintide side effects

Mild-to-moderate gut symptoms were the most common adverse event in the phase 2 trial, at rates similar to placebo in the lower-dose arms. Full detail: eloralintide dosage.

Is eloralintide legal?

Eloralintide is not approved by the FDA or any regulator I can verify, anywhere, and it is not sold anywhere. The only legitimate route to it is clinical trial enrollment. More on where research peptides stand under US law: US peptide regulation tracker.

Related reading

• Eloralintide dosage: the phase 2 trial doses
• GLP-1 peptides: how the class compares
• Cagrilintide
• Mazdutide
• Survodutide

How Eloralintide compares

GLP-1 and related medicines. Doses for unapproved compounds are common practice, not trial-established. All weight loss and metabolism peptides →

Compound	Main use	Evidence	Usual dose	US status
Eloralintide	Investigational obesity treatment in Eli Lilly's clinical trial pipeline. Not approved anywhere, not commercially available anywhere, and accessible only through clinical trial enrollment - though it is sold to consumers as an unregulated research-chemical vial under the same name.	Limited human data	No consistent protocol	Unapproved drug
Semaglutide	FDA-approved for type 2 diabetes in adults (Ozempic injection and tablets, Rybelsus), including cardiovascular risk reduction and, for the Ozempic injection, kidney-disease progression; and as Wegovy injection and tablets for chronic weight management and cardiovascular risk reduction in adults with obesity or overweight. The Wegovy injection is also approved for weight management from age 12 and for MASH with moderate to advanced liver fibrosis in adults.	Strong human evidence	FDA label	FDA-approved · prescription only
Tirzepatide	FDA-approved to improve glycemic control in type 2 diabetes in adults and children 10 years and older, and to reduce cardiovascular risk in adults with type 2 diabetes (Mounjaro), and for chronic weight management and moderate-to-severe obstructive sleep apnoea in adults with obesity (Zepbound).	Strong human evidence	FDA label	FDA-approved · prescription only
Liraglutide	FDA-approved as a once-daily injection under two brands: Saxenda, for chronic weight management alongside diet and exercise in adults and in children 12 years and older with obesity who weigh more than 60 kg, and Victoza, for glycemic control in type 2 diabetes in adults and children 10 years and older, and for reducing major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.	Strong human evidence	FDA label	FDA-approved · prescription only
Orforglipron	FDA-approved as Foundayo, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight who have at least one weight-related condition.	Strong human evidence	FDA label	FDA-approved · prescription only
Retatrutide	Investigational in Phase 3 trials for obesity, type 2 diabetes and related conditions. Not approved for any indication in the US. Sold outside the trial system as an unapproved research chemical, often alongside semaglutide and tirzepatide.	Moderate human evidence	2-12 mg, once weekly, starting at 2 mg and titrating up every 4 weeks to a 4-12 mg maintenance dose	Research use only
Survodutide	An investigational injectable peptide, not approved for any use. Its sponsor, Boehringer Ingelheim, is studying it in Phase 3 trials for chronic weight management and, in a separate programme, for MASH (metabolic dysfunction-associated steatohepatitis). It is also sold directly to consumers as a research chemical outside those trials.	Moderate human evidence	0.6-6 mg, once weekly, starting around 0.6 mg; the phase 2 trial titrated over about 20 weeks to a 2.4-4.8 mg maintenance dose, while the published phase 3 SYNCHRONIZE-1 trial randomizes to a higher 3.6 or 6.0 mg maintenance target using a slower, flexible up-titration	Research use only
Mazdutide	Approved in China for chronic weight management and for glycemic control in type 2 diabetes. Not FDA-approved in the United States, where it is sold to consumers as a research-chemical vial.	Moderate human evidence	3-9 mg, once weekly, titrated upward from a lower starting dose	Research use only

Where to buy Eloralintide for research

Each vendor is checked against my vendor checklist.

1. 1.Next Level PharmFeatured

   10 mg vial

   • No FDA warning letter found
   • Names its testing lab
   • Batch COAs published
   • Takes card payment

   $109.99as of 3 October 2026

   View product →My Next Level Pharm review

Compare every checked vendor for Eloralintide →

See all vendors and how they compare →

Common questions

What is the usual eloralintide dose?

There is none, because it isn't a marketed product. Its phase 2 trial tested fixed weekly doses of 1, 3, 6 and 9 mg, plus two step-up schedules, all under clinical supervision. Every vendor and dosing-guide page I checked says it has no separate common-practice protocol. See the dosing page for detail.

What are the side effects of eloralintide?

In Lilly's phase 2 trial, the most common adverse events were mild to moderate gut symptoms, at rates similar to placebo in the lower-dose arms. There is no long-term safety data beyond the 48-week trial.

Is eloralintide a GLP-1?

No. It selectively activates the amylin receptor, a pancreatic-hormone pathway linked to feeling full and slower stomach emptying. That is a different target from the GLP-1 receptor used by semaglutide and tirzepatide, though it is studied for the same goal of weight loss.

What is the new Eli Lilly weight loss drug?

Eloralintide (LY3841136) is one of Lilly's investigational weight-loss drugs, a once-weekly amylin-receptor injection. In its phase 2 trial, mean weight loss was 9.5% to 20.1% across doses, against 0.4% on placebo, over 48 weeks. Lilly plans Phase 3 enrollment, and it is not approved or sold anywhere.

What's the difference between cagrilintide and eloralintide?

Both are once-weekly amylin-pathway injections studied for weight loss, but they are different molecules from different companies. Lilly's eloralintide targets the amylin receptor selectively and has one published phase 2 trial. Novo Nordisk's cagrilintide also activates the calcitonin receptor and is further along: combined with semaglutide as CagriSema, it has phase 3 results and its sponsor reports it is under FDA review.

References (2 sources)

Show

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.

1. 1.Billings LK, Hsia S, Bays H et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025;406(10520):2631-2643.Randomised trialPMID 41207310
2. 2.Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight- Eli Lilly and Companyother

Keep reading

Related guides

All guides →

• bpc-157BPC-157: Benefits, Dosage, Side Effects and the ResearchWhat the BPC-157 research actually shows: benefits claims checked against a rodent literature, human dosing, side effects, and legal status.12 min readRead guide→
• 5-amino-1mq dosage5-Amino-1MQ Dosage: Common Protocol and Mouse Study DataThe 50-150 mg oral common-practice protocol for 5-Amino-1MQ, plus the one published mouse study dose - no human trial exists.4 min readRead guide→
• 5-amino-1mq5-Amino-1MQ: Capsules, Dosage, Side Effects and Legal Status5-Amino-1MQ capsules: what oral dosing was tested (in rats, not people), the 50-150 mg common protocol, mouse safety data and FDA's warning letter.5 min readRead guide→
• abaloparatideAbaloparatide (Tymlos): Uses, Dosage and Side EffectsAbaloparatide (Tymlos): the FDA-approved osteoporosis peptide - label dosing, the ACTIVE trial results, and its osteosarcoma warning.2 min readRead guide→
• abaloparatide dosageAbaloparatide Dosage: The FDA Label ScheduleAbaloparatide dosage exactly as the FDA label states it: 80 mcg once daily, the 2-year duration limit, and who should not use it.2 min readRead guide→
• adamax dosageAdamax Dosage: Why No Dose Can Be StatedAdamax dosage: only one vendor gives any figures, with no second source to check them against, and sellers disagree on what molecule is even being dosed.2 min readRead guide→